Loading…
Shandra Eisenga Human Cell and Tissue Product Safety Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2024 · fourth_quarter · Science/Technology
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act
Client expense: $30,000 · Firm income: Not reported
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
H.R.7188/S.3733 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Science/Technology
HR 7188 / S 3733, Shandra Eisenga Human Cell and Tissue Products Safety Act HR 4758 / S 2372, Accelerating Kids Access to Care Act
Client expense: $30,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
Site neutral payment Shandra Eisenga Human Cell and Tissue Product Safety Act (S. 3733/H.R. 7188) H.R. 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Site neutral payment Shandra Eisenga Human Cell and Tissue Product Safety Act (S. 3733/H.R. 7188)
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Site neutral payment Shandra Eisenga Human Cell and Tissue Product Safety Act (S. 3733/H.R. 7188)
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Issues related to HCT/P legislation (e.g. HR 7188/S. 3733)
Client expense: Not reported · Firm income: Not reported